Differences in durability of PARP inhibition by PARP inhibitors in ovarian cancer cells

Hannah L Smith 1, Elaine Willmore 2 and Nicola J Curtin 1.

1 Newcastle Centre for Cancer, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK
2 Cancer Research UK Drug Discovery Unit, Newcastle Centre for Cancer, Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK

Background

- Poly (ADP-ribose) polymerase (PARP) is the first line of defence against the commonest endogenously-induced DNA damage: single strand breaks (SSB), by promoting their repair.
- PARP inhibitors (PARPi) exploit defects in homologous recombination repair (HRR) to selectively kill tumour cells [1].
- To effectively target these HRR defective tumours PARP must be continuously inhibited, allowing cells to go through S-phase whilst inhibited [2, 3].
- 4 PARPi (rucaparib, olaparib, niraparib and talazoparib) are approved for use in cancer patients using daily dosing schedules [4].
- Pre-clinical data from 2014 showed rucaparib caused PARP inhibition in tumour xenografts for at least 7 days after a single dose [5].

Our aim was to determine if persistent PARP inhibition is unique to rucaparib or a class effect common to all approved PARPi.

Methods

A biochemical GCLP-validated assay was conducted on permeabilised cells to measure PARP activity using oligonucleotide to mimic DNA breaks and an excess of the substrate NAD+ [6]. The assay based on the following reaction:

$$\text{PARP} + \text{NAD}^+ \rightarrow \text{Nicotinamide} + \text{PARP} - \text{NAD}$$

IGROV-1 ovarian cancer cells were treated with 1 µM rucaparib, olaparib, niraparib, talazoparib or pamiparib for 1 hr before drug was washed off and replaced with fresh media. Cells were harvested and cellular PARP activity was measured and compared to untreated control and where 1 µM was added directly to permeabilised cells in the reaction.

Results

Rucaparib, olaparib, niraparib, pamiparib and talazoparib each inhibited PARP activity >99% in permeabilised cells with 1 µM added to the reaction.

- Rucaparib, olaparib, niraparib, talazoparib and pamiparib each inhibited PARP activity in permeabilised cells >99% when 1µM was present during the reaction.
- Only rucaparib maintained this level of inhibition in cells harvested immediately after exposure to PARPi, with the other inhibitors only inhibiting PARP 47-85%, suggesting failure to achieve adequate intracellular concentrations or wash-out during harvesting.

Conclusions

- Rucaparib is unique in its ability to cause persistent PARP inhibition compared to other PARPi and is not a class effect.
- These data have important clinical implications for the different uses of PARPi: for single agent activity exploiting HRR defects durable PARP inhibition is required. In contrast, for combinations with cytotoxic agents causing DNA SSBs (e.g. temozolomide, topotecan, radiotherapy) less durable PARPi may be less toxic.
- These data suggest that the current twice daily dosing approved for rucaparib treatment may not be necessary. Further studies are needed to determine whether less frequent dosing would have equivalent anticancer activity.

- After 24 h in drug-free medium rucaparib-induced PARP inhibition was maintained at 92.3 ± 4.3% but was much less with talazoparib (58.6 ± 5.0%), pamiparib (56.0 ± 4.5%) olaparib (48.3 ± 19.8%) and niraparib (37.3 ± 11.6%)
- PARP inhibition declined with time but in rucaparib-treated cells was maintained for 72h in drug-free medium (77.7 ± 12.3%). This sustained PARP inhibition was not observed with the other PARPi. PARP inhibition was only 12.3 ± 5.2% and 12.5 ± 4.9% 72h after talazoparib and niraparib, respectively, and undetectable with olaparib and niraparib.